Bisphosphonates and other bone agents for breast cancer.

Cochrane Library Logo RGB


Bone is the most common site of metastatic disease associated with breast cancer (BC). Bisphosphonates inhibit osteoclast-mediated bone resorption, and novel targeted therapies such as denosumab inhibit other key bone metabolism pathways. We have studied these agents in both early breast cancer and advanced breast cancer settings. This is an update of the review originally published in 2002 and subsequently updated in 2005 and 2012.Pulsar aquí


  • Última modificación: Viernes 17 Mayo 2019.
Real time web analytics, Heat map tracking

Menu configuración